Literature DB >> 15367040

Psychopharmacology of anticonvulsants: levetiracetam as a synaptic vesicle protein modulator.

Stephen M Stahl1.   

Abstract

ISSUE: A novel mechanism of action has recently been described for levetiracetam, a member of a new class of anticonvulsants. Levetiracetam binds selectively and with high affinity to a synaptic vesicle protein known as SV2A, thought to be involved with synaptic vesicle exocytosis and presynaptic neurotransmitter release.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15367040     DOI： 10.4088/jcp.v65n0901

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


  6 in total

1.  Seizure prophylaxis and melanoma brain metastases.

Authors:  S A Goldlust; M Hsu; A B Lassman; K S Panageas; E K Avila
Journal:  J Neurooncol       Date:  2012-02-05       Impact factor: 4.130

Review 2.  Levetiracetam: a review of its use in epilepsy.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2011-03-05       Impact factor: 9.546

3.  Expression of synaptic vesicle protein 2A in epilepsy-associated brain tumors and in the peritumoral cortex.

Authors:  Marjolein de Groot; Sjoukje T Toering; Karin Boer; Wim G M Spliet; Jan J Heimans; Eleonora Aronica; Jaap C Reijneveld
Journal:  Neuro Oncol       Date:  2010-01-06       Impact factor: 12.300

4.  Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors.

Authors:  Herbert B Newton; Jennifer Dalton; Samuel Goldlust; Dennis Pearl
Journal:  J Neurooncol       Date:  2007-04-13       Impact factor: 4.506

5.  A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam.

Authors:  Ciarán Campbell; Mark McCormack; Sonn Patel; Caragh Stapleton; Dheeraj Bobbili; Roland Krause; Chantal Depondt; Graeme J Sills; Bobby P Koeleman; Pasquale Striano; Federico Zara; Josemir W Sander; Holger Lerche; Wolfram S Kunz; Kari Stefansson; Hreinn Stefansson; Colin P Doherty; Erin L Heinzen; Ingrid E Scheffer; David B Goldstein; Terence O'Brien; David Cotter; Samuel F Berkovic; Sanjay M Sisodiya; Norman Delanty; Gianpiero L Cavalleri
Journal:  Epilepsia       Date:  2022-04-01       Impact factor: 6.740

6.  Evaluating the In Vivo Specificity of [18F]UCB-H for the SV2A Protein, Compared with SV2B and SV2C in Rats Using microPET.

Authors:  Maria Elisa Serrano; Guillaume Becker; Mohamed Ali Bahri; Alain Seret; Nathalie Mestdagh; Joël Mercier; Frédéric Mievis; Fabrice Giacomelli; Christian Lemaire; Eric Salmon; André Luxen; Alain Plenevaux
Journal:  Molecules       Date:  2019-05-01       Impact factor: 4.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.